Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | MBTPS1 | Q14703 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884898 | 1.00 | FPR1 (0.44) | FPR1FPR2HTR6MBTPS1HTR2A | |
| SCHEMBL4884905 | 1.00 | FPR1 (0.44) | FPR1FPR2HTR6MBTPS1HTR2A | |
| SCHEMBL4882366 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR6HTR2CHTR2B | |
| SCHEMBL4882383 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR6HTR2CHTR2B | |
| SCHEMBL4882358 | 0.90 | FPR1 (0.44) | FPR1FPR2HTR6HTR2CHTR2B | |
| SCHEMBL4886745 | 0.85 | HTR6 (0.43) | FPR1FPR2HTR6MBTPS1HTR2A | |
| SCHEMBL4886751 | 0.85 | HTR6 (0.43) | FPR1FPR2HTR6MBTPS1HTR2A | |
| SCHEMBL4886739 | 0.85 | HTR6 (0.43) | FPR1FPR2HTR6MBTPS1HTR2A | |
| SCHEMBL4881798 | 0.84 | HTR6 (0.41) | HTR6MBTPS1HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4881806 | 0.84 | HTR6 (0.41) | HTR6MBTPS1HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | FPR1 4794/4885FPR2 4698/4885HTR6 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.